Işeri 2007.

Methods	30‐day prospective cohort study of methylphenidate
Participants	Number of participants screened: 428 Number of participants included: 20 Number of participants followed up: 20 Number of withdrawals: 0 Diagnosis of ADHD: DSM‐IV (subtype: combined 100%) Age: mean 9.27 (SD 1.59), range: 6‐12 years old IQ: normal Sex: 20 males Methylphenidate‐naïve: 100% Ethnicity: not stated Country: Turkey Comorbidity: ODD 35% Comedication: none Sociodemographics: not stated Inclusion criteria Pre‐pubertal children aged 6‐12 years old ADHD DSM‐IV diagnosis No previous methylphenidate treatment No history or current co‐morbid psychiatric condition apart from ODD Male Exclusion criteria Intellectual disability or developmental delay History of head injury Any other neurological, metabolic or infectious disorder Liver or kidney dysfunction Routine use of any drugs
Interventions	Methylphenidate type: short‐acting Methylphenidate dosage: 0.6 mg/kg/day Administration schedule: not stated Duration of intervention: 30 days Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Severity (0: not a problem, 1: mild, 2: moderate, 3: severe) of 13 possible side effects rated by mothers Appetite status (0: not a problem, 1: mild, 2: moderate, 3: severe) rated by mothers before and after medication Height and weight were measured before and after treatment and BMI was calculated. The patients were instructed not to change diet or physical activity during the study
Notes	Sample calculation: not stated Ethics approval: approved by the institutional ethical committee Funding: Gazi University Scientific Project Fund Key conclusions of the study authors: short‐acting methylphenidate does not affect leptin appetite at 0.6 mg/kg/day dose. Did not show significant difference between pre‐ and postleptin levels Comments from the study authors: limitations of the study: small sample size, short duration of the study, only 1 dose of methylphenidate Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: all participants were methylphenidate‐naïve Supplemental data regarding the vomiting and skin eruptions have not been possible to receive from the authors. We have tried to get in contact with them twice without success